ASLAN Pharmaceuticals Limited
ASLN · NASDAQ
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | -0.01 | -0.00 | 0.17 |
| FCF Yield | 0.00% | 0.00% | 0.00% | 0.00% |
| EV / EBITDA | -3.32 | -1.90 | -7.27 | -167.19 |
| Quality | ||||
| ROIC | -106.79% | -95.17% | -27.91% | -5.51% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 100.00% |
| Cash Conversion Ratio | – | – | – | 0.43 |
| Growth | ||||
| Revenue 3-Year CAGR | 2,289,328.49% | 2,289,328.49% | 2,289,328.49% | 2,289,328.49% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -0.89 | -0.45 | 0.29 | 4.31 |
| Interest Coverage | -13.95 | -12.94 | -9.21 | -2.10 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 90.00 |